Your browser is no longer supported. Please, upgrade your browser.
Settings
LEGN Legend Biotech Corporation daily Stock Chart
LEGN [NASD]
Legend Biotech Corporation
Index- P/E- EPS (ttm)-2.46 Insider Own- Shs Outstand132.16M Perf Week11.69%
Market Cap4.15B Forward P/E- EPS next Y-0.63 Insider Trans- Shs Float11.87M Perf Month15.02%
Income-309.60M PEG- EPS next Q-0.28 Inst Own18.70% Short Float9.94% Perf Quarter9.54%
Sales54.30M P/S76.46 EPS this Y- Inst Trans-0.22% Short Ratio4.78 Perf Half Y-10.28%
Book/sh2.53 P/B12.80 EPS next Y54.00% ROA- Target Price50.67 Perf Year-
Cash/sh4.50 P/C7.20 EPS next 5Y- ROE- 52W Range24.64 - 43.24 Perf YTD-12.46%
Dividend- P/FCF- EPS past 5Y- ROI119.40% 52W High-25.09% Beta-
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low31.45% ATR1.53
Employees645 Current Ratio4.90 Sales Q/Q-33.90% Oper. Margin- RSI (14)70.38 Volatility5.40% 5.40%
OptionableYes Debt/Eq0.01 EPS Q/Q-134.30% Profit Margin- Rel Volume1.61 Prev Close31.45
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume246.86K Price32.39
Recom1.70 SMA2015.07% SMA5013.72% SMA200-0.39% Volume398,059 Change2.99%
Jul-01-20Initiated JP Morgan Overweight $50
Jul-01-20Initiated Jefferies Buy $47
Jun-30-20Initiated Morgan Stanley Overweight $55
Dec-05-20 03:00PM  
Dec-03-20 08:00AM  
Nov-24-20 08:00AM  
Nov-23-20 07:00AM  
Nov-16-20 07:00AM  
Nov-09-20 11:06AM  
Nov-05-20 07:05AM  
Nov-01-20 10:18AM  
Oct-22-20 05:03PM  
Oct-08-20 09:41PM  
08:21PM  
04:30PM  
Oct-07-20 04:00PM  
03:00PM  
Oct-06-20 11:10PM  
08:10PM  
06:03PM  
08:00AM  
Oct-05-20 04:39PM  
Oct-02-20 02:50PM  
Sep-30-20 06:22PM  
01:40PM  
Sep-29-20 08:00PM  
11:23AM  
Sep-28-20 11:00PM  
04:30PM  
Sep-27-20 01:24AM  
Sep-26-20 04:00PM  
Sep-25-20 02:23PM  
10:00AM  
08:00AM  
Sep-24-20 02:10PM  
11:27AM  
Sep-23-20 11:00PM  
04:38PM  
01:45PM  
08:51AM  
Sep-22-20 07:28PM  
07:00PM  
05:00PM  
01:58PM  
12:53PM  
11:30AM  
Sep-21-20 10:55PM  
09:56PM  
05:44PM  
03:45PM  
01:57PM  
01:39PM  
11:00AM  
09:00AM  
06:30AM  
Sep-08-20 10:20AM  
Sep-01-20 04:00PM  
Aug-28-20 04:34PM  
Aug-05-20 05:37PM  
Aug-02-20 11:02AM  
10:43AM  
Jul-08-20 12:53PM  
Jun-16-20 05:34PM  
Jun-09-20 04:35PM  
04:30PM  
Jun-05-20 05:48PM  
03:45PM  
12:07PM  
08:35AM  
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.